EBV EBNA3A (325-333) (HLA-B8) FLRGRAYGL-acid

Description

EBV EBNA3A (325-333) (HLA-B8) is an immunodominant CEF control peptide that is derived from the Epstein-Barr virus (EBV).

See full description

Catalogue number crb1001460
Sequence (one letter code) FLRGRAYGL-acid
Sequence (three letter code) H-Phe-Leu-Arg-Gly-Arg-Ala-Tyr-Gly-Leu-OH
Purity >95%
Storage -20°C
Molecular Weight 1051.6

EBV EBNA3A (325-333) (HLA-B8) is an immunodominant CEF control peptide that is derived from the Epstein-Barr virus (EBV). EBV targets B cells, which can cause lytic infection and consequently the death of these cells. Natural killer (NK) cells, invariant (iNKT) cells, CD4T cells and CD8 T cells are essential to control the action of EBV-infected cells. EBV EBNA3A (325-333) (HLA-B8) is defined as a CEF control peptide due to its antigenic properties. Clinically, these peptides are suitable epitopes for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-B8 refers to the cell HLA type that this peptide acts on in such experiments.


The EBNA3A protein plays a significant role in reprogramming the gene expression of host cells. The action of this protein affects cell proliferation, survival, differentiation and immune surveillance. EBNA3A also targets tumour suppressor pathways in the infected B cells, meaning it is considered an oncoprotein.

EBV EBNA3A (325-333) (HLA-B8)

Cat No. Pack Size Price Qty

crb1001460h

0.5mg

$112.50

crb1001460j

1mg

$150.00